BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
4.980
-0.250 (-4.78%)
At close: Aug 22, 2025, 4:00 PM
5.00
+0.02 (0.40%)
After-hours: Aug 22, 2025, 7:59 PM EDT
BioXcel Therapeutics Employees
BioXcel Therapeutics had 37 employees as of December 31, 2024. The number of employees decreased by 37 or -50.00% compared to the previous year.
Employees
37
Change (1Y)
-37
Growth (1Y)
-50.00%
Revenue / Employee
$23,459
Profits / Employee
-$1,377,027
Market Cap
72.49M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 37 | -37 | -50.00% |
| Dec 31, 2023 | 74 | -109 | -59.56% |
| Dec 31, 2022 | 183 | 94 | 105.62% |
| Dec 31, 2021 | 89 | 39 | 78.00% |
| Dec 31, 2020 | 50 | 26 | 108.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BTAI News
- 4 days ago - BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire
- 5 days ago - BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire
- 10 days ago - BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series - GlobeNewsWire
- 11 days ago - BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates - GlobeNewsWire
- 12 days ago - BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
- 17 days ago - BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies - GlobeNewsWire
- 22 days ago - BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire
- 4 weeks ago - BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI® - GlobeNewsWire